The CCL2-CCR2 and CCL5-CCR5 chemokine signalling axes stimulates monocyte recruitment to insulted adipose tissue sites and has been suggested as therapeutic target to resolve inflammation in NAFLD (Kazankov et al., 2019). Here, CCL2 is linked to metabolic dysfunction-associated steatotic liver disease.